Design, Synthesis and Biological Evaluation of Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors

The diacylglycerol kinase alpha (DGKα) is an important player in signal transduction, phosphorylating the membrane lipid diacylglycerol to phosphatidic acid. Emerging data indicate that DGKα mediates T cell dysfunction during anti-PD-1 therapy, having a marked impact on the development of resistance to PD-1 blockade. Here, we report the discovery of compound <b>10</b> as a novel, potent, selective, and orally available DGKα inhibitor with a promising ADME profile. More importantly, compound <b>10</b> significantly enhanced the <i>in vivo</i> antitumor activities by combination with anti-PD-1 or anti-CTLA-4 in different mouse models, and obvious synergistic effects were observed.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-12-01
DOI
https://doi.org/10.1021/acs.jmedchem.5c01943
Citations
1
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design, Synthesis and Biological Evaluation of Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors

Haoyu Zhang, Alex Zhavoronkov, Ruizheng Shi, Huaxing Yu et al.
1 citations
Journal of Medicinal Chemistry
Protein Kinase Regulation and GTPase Signaling
0.81
article

Design, Synthesis and Biological Evaluation of Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors

Haoyu Zhang, Alex Zhavoronkov, Ruizheng Shi, Huaxing Yu, Deheng Sun, Alexander Aliper, Man Zhang, Shan Chen, Jinxin Liu, Xiao Ding, Xin Cai, Hui Cui, Feng Ren, Hongfu Lu, Sujing Shi
article en
1 citations

Abstract

The diacylglycerol kinase alpha (DGKα) is an important player in signal transduction, phosphorylating the membrane lipid diacylglycerol to phosphatidic acid. Emerging data indicate that DGKα mediates T cell dysfunction during anti-PD-1 therapy, having a marked impact on the development of resistance to PD-1 blockade. Here, we report the discovery of compound <b>10</b> as a novel, potent, selective, and orally available DGKα inhibitor with a promising ADME profile. More importantly, compound <b>10</b> significantly enhanced the <i>in vivo</i> antitumor activities by combination with anti-PD-1 or anti-CTLA-4 in different mouse models, and obvious synergistic effects were observed.

Journal of Medicinal ChemistryVol. 68(23)
Hong Kong Science and Technology Parks Corporation (HK), La Jolla Alcohol Research (US), Insilico Medicine (United States)
Openalex Percentile: Top 21%
Protein Kinase Regulation and GTPase Signaling
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.